All in the Genes
By Marcy Darnovsky and Hank Greely,
Democracy
| 08. 31. 2008
Henry Greely inaccurately characterizes my organization, the Center for Genetics and Society, as "drawn to arguments against [inheritable human genetic enhancement] by the lure of naturalness" ["The Genetics of Fear," Issue #9].
I am not sure how Greely reached this conclusion. We explicitly ground our opposition in our commitments to social justice and equality. Procedures that produce (or claim to produce) genetically superior children for those with access to expensive technologies would all too likely exacerbate inequalities and lead to new forms of discrimination.
Greely seems enthusiastic about inheritable genetic modification, but he also recognizes that significant improvements are a long way off. He therefore dismisses proposals, such as the one offered by Jamie Metzl, for international agreements to prohibit socially undesirable human biotechnologies ["Brave New World War," Issue #8]. He disparages efforts at international regulation as "neither progressive nor wise," without mentioning that similar regulations are already in effect, and working well, in over four dozen countries. The United States should join this growing international consensus.
Greely warns ominously that regulating biotechnology "would almost certainly...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...